The market for weight-loss drugs is projected to surge to $150 billion as supply increases. Companies like Viking Therapeutics ($VKTX), Eli Lilly ($LLY), and Novo Nordisk ($NVO) are expected to dominate the market over the next decade. Viking Therapeutics' VKTX 2735 stands out for its tolerability and safety profile, which could give it an edge in the competitive obesity drug market. The total addressable market (TAM) for obesity and co-morbidities is significant over the next 5-10 years. The historical success of statin drugs, from Lovastatin in 1987 to Crestor in 2003 by AstraZeneca ($AZN), suggests a similar long-term profitability for obesity drugs.
other obesity players out there - but so far $VKTX 2735 Tolerability standing out more and more - $VKTX 2735 profile differentiated from the others https://t.co/WgN8ly6wt8
Sooner or later market will realize how $VKTX has the edge over others in safety which is very crucial for obesity drugs adoption rates
$VKTX on the move
Obesity drugs will rule the market for next decade or so $VKTX $LLY $NVO Here's a quick reference to Statin drugs. From Lovastatin approval in 1987 to all the way to Crestor approval by $AZN in 2003, big pharma continued to enjoy big gains from Statin revenues for decades. https://t.co/saIqggfxhN
Obesity and co-morbidities TAM $VKTX Next 5-10 years https://t.co/AdIWjuLaMJ
Weight-loss drug forecasts jump to $150 billion as supply grows https://t.co/BxL8hB6lCk https://t.co/BxL8hB6lCk